The purpose of this study is to assess the abuse liability and reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in heroin-dependent volunteers

Condition	Treatment or Intervention	Phase
Heroin Dependence Opioid-Related Disorders	Drug: Opioid-Related Disorders	Phase II

Further Study Details: 

not available at this time

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

Individuals must be at least 18 yrs of age, currently opioid dependent and must not be seeking treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.

Exclusion Criteria:

Individuals with evidence of an active DSM-IV Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Colorado
      University of Colorado Health Sciences Center, Denver,  Colorado,  80206,  United States

Study chairs or principal investigators

Leslie Amass, Ph.D.,  Principal Investigator,  University of Colorado   

Study ID Numbers:  NIDA-11160-5; R01-11160-5
Record last reviewed:  October 1999
Last Updated:  February 16, 2005
Record first received:  September 20, 1999
ClinicalTrials.gov Identifier:  NCT00000330
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08